Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 27 (11) 1800-1805
Year:
2009
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
679  
Children:
None
Program:
OGC
Primary Committee:
Experimental
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA047577, CA33601, CA77597, CA11789, U10 CA077658, U10 CA031983, CA02599, CA47577, CA41287, CA03927, U10 CA031946, CA77651, U10 CA033601, U10 CA077597, P30 CA023108, U10 CA004326, U10 CA041287, U10 CA047559, U10 CA077651, CA04326, CA47559, CA47642, CA77658, U10 CA047642, CA31983, CA31946, U10 CA003927  
Corr. Author:
 
Authors:
                                   
Networks:
 
Study
CALGB-60301
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
1
Keywords:
Faze, Original Reports, Phase I and Clinical Pharmacology